Capricor Therapeutics, Inc. (NASDAQ:CAPR – Get Free Report) CFO Anthony Bergmann sold 24,100 shares of the firm’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $30.38, for a total value of $732,158.00. Following the transaction, the chief financial officer directly owned 11,223 shares in the company, valued at approximately $340,954.74. This represents a 68.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website.
Anthony Bergmann also recently made the following trade(s):
- On Monday, June 22nd, Anthony Bergmann sold 500 shares of Capricor Therapeutics stock. The stock was sold at an average price of $30.00, for a total value of $15,000.00.
- On Wednesday, June 24th, Anthony Bergmann sold 400 shares of Capricor Therapeutics stock. The shares were sold at an average price of $30.00, for a total transaction of $12,000.00.
- On Friday, May 1st, Anthony Bergmann sold 25,000 shares of Capricor Therapeutics stock. The stock was sold at an average price of $31.70, for a total transaction of $792,500.00.
Capricor Therapeutics Stock Performance
Shares of CAPR opened at $24.08 on Wednesday. Capricor Therapeutics, Inc. has a fifty-two week low of $4.30 and a fifty-two week high of $40.37. The firm has a market cap of $1.39 billion, a price-to-earnings ratio of -10.38 and a beta of 0.39. The firm has a 50 day moving average price of $29.58 and a 200-day moving average price of $28.35.
Wall Street Analyst Weigh In
Several brokerages recently weighed in on CAPR. Weiss Ratings restated a “sell (d-)” rating on shares of Capricor Therapeutics in a report on Monday, June 15th. B. Riley Financial lifted their price target on Capricor Therapeutics from $50.00 to $63.00 and gave the stock a “buy” rating in a research note on Friday, March 13th. HC Wainwright reiterated a “buy” rating and issued a $60.00 price objective on shares of Capricor Therapeutics in a research report on Wednesday, May 13th. Piper Sandler reissued an “overweight” rating and set a $58.00 price objective (up from $45.00) on shares of Capricor Therapeutics in a research note on Friday, March 13th. Finally, Cantor Fitzgerald set a $62.00 target price on shares of Capricor Therapeutics and gave the stock an “overweight” rating in a report on Friday, March 13th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Capricor Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $53.67.
Get Our Latest Stock Analysis on Capricor Therapeutics
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of CAPR. Glenmede Trust Co. NA lifted its holdings in Capricor Therapeutics by 13.2% in the 1st quarter. Glenmede Trust Co. NA now owns 36,330 shares of the biotechnology company’s stock worth $1,104,000 after buying an additional 4,240 shares during the period. Bank of America Corp DE increased its stake in shares of Capricor Therapeutics by 672.0% during the first quarter. Bank of America Corp DE now owns 415,483 shares of the biotechnology company’s stock valued at $12,631,000 after buying an additional 361,664 shares during the period. Stempoint Capital LP increased its stake in shares of Capricor Therapeutics by 110.6% during the first quarter. Stempoint Capital LP now owns 37,592 shares of the biotechnology company’s stock valued at $1,143,000 after buying an additional 19,739 shares during the period. Janus Henderson Group PLC purchased a new position in shares of Capricor Therapeutics during the first quarter valued at approximately $687,000. Finally, Ally Bridge Group NY LLC bought a new position in shares of Capricor Therapeutics during the first quarter valued at approximately $3,463,000. Institutional investors own 21.68% of the company’s stock.
Capricor Therapeutics Company Profile
Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.
The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.
Featured Stories
- Five stocks we like better than Capricor Therapeutics
- NextEra’s Dominion Deal Could Put It at the Center of the AI Power Race
- Amazon Could Be About to Reap the Rewards of a Software Spending Boom
- Best Buy’s Turnaround Is Gaining Traction, But Wall Street Still Needs Proof
- AI Fears Hit Nebius Stock, But Has the Growth Thesis Changed?
Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
